Indeed, Konopleva’s group demonstrated that hypoxia conditions activate the Akt/mTOR pathway, while exposure to everolimus—one of the first mTOR inhibitors that were approved by the FDA for clinical use in the treatment of patients with cancer [31]—deactivates HIF1α, reverting the glycolytic phenotype of the ALL cell line [32]. Here, AKT1 is linked to cancer.